Skip to main content
OpenTrials
Completed

NCT Number: NCT04519203

The Use of Surgical Pleth Index in Guiding Anesthesia in Gastroenterological Surgery

Surgical Pleth Index (SPI) is an intraoperative monitor aimed into detection of nociception and guidance of intraoperative opioid administration. Using such a device opioid administration could be potentially optimized during intraoperative period. this study will aim to show whether SPI could be used to reduce unwanted events and lower opioid consumption in gastroenterological surgery. The study will be blinded and randomized including two study arms with either SPI monitoring included or standard monitoring alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tampere University Hospital

Tampere, 33521, Finland

About this study

Patients are extensively monitored intraoperatively. Even though there are monitors for the measurement of nociception, it has not gained wide acceptance partly because of limited and scarce evidence on the efficacy and optimal use. Especially elderly patients undergoing major operation might benefit from optimization of opioid administration. Surgical Pleth Index (SPI) is an intraoperative monitoring aimed for detection of nociceptive stimulus.

The aim of this research is to study whether SPI could be used to guide opioid administration in gastroenterological surgery. The study will consist of a total 80 patients which are randomized into two groups. The study sample is based on power calculation for the reduction of remifentanil consumption.

In the study group the opioid administration will be guided using a SPI based protocol. In the control group the opioid administration will be based on standard monitoring and clinical decision alone. The aim of the study will be to study whether opioid administration optimized using SPI can lover need for anticholinergic drugs, reduce need for opioids or diminish the amount of unwanted side effects postoperatively. The patients will be treated using target controlled infusions of remifentanil and propofol.

The data will be collected intraoperatively using electronic software and using a study data collection form by study personel. All study procedures will take place during operative period.

The study power was calculated using a study comparing depth of anesthesia and depth of nociception balance-controlled group into a group without these monitors. In the group with monitoring the consumption of remifentanil was 9,5±3.8 mg/kg/h while in the unmonitored group the consumption was 12.3 mg/kg/h(Chen, 2010). While taking into notice α= 0,005 and β=90% a number of 39 patients in each group is needed. Based on these we chose 80 patients to be included in the study.

All collected data will be used into statistical analysis ass applicable. Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to provide a written informed consent
  • Age 50 years or above
  • Laparoscopic or laparotomic surgery requiring intubation with an expected intraoperative time at least two hours.
  • ASA classification 1-3

Exclusion criteria

  • Implanted cardiac pacemaker or known condition with irregular heart rate at the time of inclusion or induction
  • Chronic use of opioids
  • BMI >35
  • Known allergy for study medications
  • Over 5 extrasystoles per minute at the time of induction or inclusion
  • The use of epidural catheter during the last one hour before surgery or need for catheter intraoperatively (if new catheter is placed at the beginning of surgery test dosage may be used without the need for patient exclusion)

Treatment and study plan

SPI

Device

Either standard monitoring alone or added with SPI

Standard

Device

Standard monitoring alone

Primary outcomes

  1. Intraoperative remifentanil consumption

    Time frame: intraoperative time

    The consumption of the remifentanil intraoperatively

Secondary outcomes

  1. severe hypotension

    Time frame: intraoperative time

    MAP <55 mmHg, or -30% from the baseline value

  2. intermediate hypotension

    Time frame: intraoperative time

    MAP <65 mmHg, or -20% from the baseline value

  3. hypertension

    Time frame: intraoperative time

    RRsys >140 mmHg or +20 % from baseline value

  4. Bradycardia

    Time frame: intraoperative time

    Heart rate<45

  5. tachycardia

    Time frame: intraoperative time

    Heart rate>90

  6. Inraoperative propofol consumption

    Time frame: intraoperative time

  7. Desorientation/ grade of sedation during postoperative care treatment

    Time frame: 2-4 hours

    The postoperative desoroentation during immediate post-operative period at postanesthesia care unit. Measured using modified aldrete score

  8. Postoperative nausea and vomiting

    Time frame: 2-4 hours

    The postoperative nausea and vomiting during immediate post-operative period at postanesthesia care unit. Measured using modified aldrete score.

  9. Postoperative opioid consumption

    Time frame: 2-4 hours

    The postoperative opioid consumption during immediate post-operative period at postanesthesia care unit.

  10. Fading of intraoperative relaxation

    Time frame: intraoperative time

    The characteristics of intraoperative relaxation using EMG measurement

Sponsors and collaborators

Lead sponsor

Tampere University Hospital

Other

Collaborators

  • general electric healthcare Finland

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Aug 19, 2020
Registry last updated
Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.